pegaspargase (Oncaspar)

09/01/2008 - "Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study."
08/01/2007 - "In recent years, clinical trials have established the importance of intramuscular PEG-asparaginase in frontline pediatric and adult acute lymphoblastic leukemia therapy. "
01/01/2015 - "Pegaspargase is used to treat acute lymphocytic leukemia (ALL). "
05/01/2014 - "Pegaspargase (PEG) is a standard component of therapy for pediatric acute lymphoblastic leukemia (ALL). "
03/20/2014 - "Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia."

07/01/2015 - "Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China."
01/01/2014 - "Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma."
06/15/1987 - "These results indicate that PEG-asparaginase has antitumor activity in dog with spontaneously occurring malignant lymphoma."
05/01/2015 - "A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma."
05/01/2015 - "To evaluate the maximum tolerated dose, safety profile, pharmacokinetics, and pharmacodynamics of pegaspargase (PEG-ASP) in combination with gemcitabine in patients with advanced metastatic solid tumors and lymphoma. "

03/01/2015 - "The objective of this study was to describe the clinical aspects of PEG-asparaginase allergy in children treated according to the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol. "
03/01/2013 - "In the ongoing trial AIEOP-BFM ALL 2009 (Associazione Italiana Ematologia Oncologia Pediatrica - Berlin-Franklin-Munster), in which PEG-asparaginase is used first-line, one dose of PEG-asparaginase is substituted by seven doses of crisantaspase given intravenously at 20,000 IU/m2 on alternate days when clinical allergy or silent inactivation is present. "
08/01/2015 - "Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review."
03/01/2015 - "Clinical allergy to PEG-asparaginase occurred early in treatment, was in general moderate in severity, and mostly developed within 2 hr after PEG-asparaginase administration. "
03/01/2015 - "PEG-asparaginase allergy occurred after a median of two doses (75% range 2-4, max 14). "

11/01/2001 - "Use of PEG-asparaginase in the treatment of patients with solid tumors."
02/18/2010 - "Between 2005 and 2007, 197 patients (age, 1-17 years) were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-01 and received a single dose of intravenous PEG-asparaginase (2500 IU/m(2)) over 1 hour during remission induction. "
12/01/2015 - "The aim of the Dana-Farber Cancer Institute Acute Lymphoblastic Leukaemia Consortium Protocol 05-001 (DFCI 05-001) was to compare the relative toxicity and efficacy of intravenous PEG-asparaginase and intramuscular native E colil-asparaginase in children with newly diagnosed acute lymphoblastic leukaemia. "
05/01/2015 - "A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma."
03/01/2002 - "A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962)."

02/01/2014 - "[Advances on the role of pegaspargase in the treatment of childhood leukemia]."
03/01/2011 - "We describe a pediatric patient with acute leukemia who developed an uncommon but significant metabolic consequence of pegaspargase therapy-severe hypertriglyceridemia (hyperTG). "
05/01/2010 - "AREAS COVERED BY THIS REVIEW: The search terms used were asparaginase, leukemia, pegylated, oncaspar, adolescent and young adult. "
09/01/1995 - "Pegaspargase offers leukemia patients adequate asparagine depletion with a reduced incidence of hypersensitivity. "
08/01/2001 - "Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein."